Tag - BIIB

Biogen (NASDAQ:BIIB) and partner Eisai are discontinuing two global Phase 3 trials to evaluate the efficacy and safety of aducanumab in Alzheimer’s disease (AD). Aducanumab is a monoclonal antibody designed to slow AD...